GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LivaNova PLC (FRA:LIA) » Definitions » Cash And Cash Equivalents

LivaNova (FRA:LIA) Cash And Cash Equivalents : €683 Mil (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is LivaNova Cash And Cash Equivalents?

LivaNova's quarterly cash and cash equivalents increased from Sep. 2024 (€312.08 Mil) to Dec. 2024 (€409.56 Mil) and increased from Dec. 2024 (€409.56 Mil) to Mar. 2025 (€683.05 Mil).

LivaNova's annual cash and cash equivalents increased from Dec. 2022 (€202.18 Mil) to Dec. 2023 (€244.38 Mil) and increased from Dec. 2023 (€244.38 Mil) to Dec. 2024 (€409.56 Mil).


LivaNova Cash And Cash Equivalents Historical Data

The historical data trend for LivaNova's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LivaNova Cash And Cash Equivalents Chart

LivaNova Annual Data
Trend Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 207.83 184.07 202.18 244.38 409.56

LivaNova Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 284.46 305.86 312.08 409.56 683.05

LivaNova Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


LivaNova  (FRA:LIA) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


LivaNova Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of LivaNova's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


LivaNova Business Description

Traded in Other Exchanges
Address
20 Eastbourne Terrace, London, GBR, W2 6LG
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

LivaNova Headlines

No Headlines